The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of product releases and the ramp-up of its new acquired manufacturing facility, and confirmed its guidance for the full year.
Related Posts
Insurers Pocketed $50 Billion From Medicare for Diseases No Doctor Treated
Questionable diagnoses of HIV and other maladies triggered extra Medicare Advantage payments. “It’s anatomically impossible,” said one doctor about some cataract diagnoses.
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Five Below CEO Joel Anderson Steps Down
Five Below replaced its longtime chief executive and cut its outlook for the second quarter as the discount retailer continues to grapple with slower consumer […]